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Summary 
We studied the effects of growth hormone (GH), insulin-like growth factor I (IGF-t), IGF-II, 
and insulin on human immunoglobulin E (IgE) and IgG4 production. GH and IGF-I induced 
IgE and IgG4 production by normal donors' mononuclear cells (MNC) depleted of slgE + and 
slgG4 + B cells without affecting IgM, IgG1, IgG2, IgG3, IgA1, or IgA2 production, whereas 
IGF-II and insulin failed to do so. GH-induced IgE and IgG4 production was specific, and was 
not mediated by IGF-I, interleukin 4 (IL-4), or IL-13, since it was blocked by anti-GH antibody 
(Ab), but not by anti-IGF-I Ab, anti-IL-4 Ab, or anti-IL-13  Ab. Conversely,  IGF-I-induced 
IgE and IgG4 production was blocked by anti-IGF-I Ab, but not by anti-GH Ab, anti-IL-4 Ab, 
or anti-IL-13 Ab. Moreover, interferon ot (IFN-cx) or IFN-'y, which counteracted IL-4- and IL-13-in- 
duced IgE and IgG4 production, had no effect on induction by GH or IGF-I. In contrast to 
MNC, GH or IGF-I failed to induce IgE and IgG4 production by purified slgE-,  slgG4-  B 
cells. However, in the presence of anti-CD40 monoclonal antibody (mAb), GH or IGF-I induced 
IgE and IgG4 production by these cells. Purified slgE +, but not slgE-, B cells from atopic pa- 
tients spontaneously produced IgE. GH or IGF-I with anti-CD40 mAb failed to enhance IgE 
production by slgE + B cells, whereas they induced IgE production by slgE- B cells. Similarly, 
whereas GH or IGF-I with anti-CD40 mAb failed to enhance IgG4 production by slgG4 + B 
cells from atopic patients, they induced IgG4 production by slgG4- B cells. Again, neither IgE 
nor IgG4 induction was blocked by anti-IL-4 Ab or anti-IL-13  Ab. These results indicate that 
GH and IGF-I induce IgE and IgG4 production by class switching in an IL-4- and IL-13-inde- 
pendent mechanism. 
I 
n mononuclear cells (MNC), IL-4 induces IgE and IgG4 
production, which can be inhibited by IFN-cr or IFN-'y 
(1-3).  In contrast, IL-4 alone cannot induce IgE and IgG4 
production by purified B cells. However, IL-4 plus anti-CD40 
mAb induces IgE and IgG4 production which is not inhibited 
by IFN-c~ or IFN-3' (3-6). We and others (7, 8) have reported 
that T cells from patients with hyper IgE syndrome or atopy 
secrete IgE-enhancing activity that was not IL-4.  We also 
found that  IgE  and  IgG4 production was  modulated by 
erythropoietin and neuropeptides in an IL-4-, IFN-cx-, and 
IFN-3,-independent fashion (9,  10). These results  indicate 
that there may be another IgE- and IgG4-inducing cytokine(s). 
Indeed, IL-13 has been shown to induce IgE and IgG4 produc- 
tion in IL-4-independent mechanisms although there are com- 
monalities between the IL-4 and IL-13 receptor, and it is still 
possible that other factors may be involved in induction of 
IgE and IgG4 production (11, 12). 
We have recently reported that growth hormone (GH) and 
insulin-like growth factor I (IGF-I) enhanced IgE and IgG4 
production by human plasma cell line and plasma cells, whereas 
IGF-II or insulin failed to do so (13). We therefore studied 
whether GH and IGF-I would induce IgE and IgG4 produc- 
tion by normal B cells. Because hormones in serum modu- 
lated the GH-induced response, we compared the effects of 
peptides in serum- and hormone-free medium, DME/F-12 
(13, 14). We show that GH and IGF-I, but not IGF-II or 
insulin, induce IgE and IgG4 production by tonsillar slgE-, 
slgG4- B cells in an IL-4- and IL-13-independent fashion. 
Materials and Methods 
Reagents.  The following  recombinant  human cytokines  and Abs 
were kindly provided  by companies  described  previously  (2, 3): II:4 
and rabbit anti-I1:4 Ab (Ono Pharmaceutical Company, Osaka, 
Japan), IFN-cr and IFN-'y (Takeda Chemical Industries, Osaka, 
Japan), and GH and rabbit anti-GH Ab (Sumitomo Pharmaceu- 
ticals, Osaka, Japan). Mouse IgG1 anti-GH receptor mAb (MAB 
263) was purchased from Agen Biomedical  Ltd. (Qld, Australia  ) 
(13). Human recombinant I1:13 was purchased from Pepro Tech 
Inc. (Rocky Hill, NJ). Human recombinant IGF-I, IGF-II, insulin, 
rabbit anti-IGF-I Ab, mouse IgG1 anti-IGF-I receptor mAb (cdP,- 
3), mouse IgM anti-CD40 mAb (MA6), rabbit anti-I1:13 Ab, con- 
trol rabbit IgG, and control mouse IgG1 were purchased from 
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a serum- and hormone-flee type, DME, supplemented with Ham's  s- 
Nutrient (DME/F-12) (Sigma  Chemical  Co., St. Louis,  MO), 0.5%  ~  6- 
BSA, and 50/zg/ml transferrin (14). 
Cell Cultures.  Tonsillar MNC were obtained from nonatopic  ~  4- 
donors (serum IgE level <50 U/ml) and atopic patients (serum IgE  z- 
level 1,129-13,129 U/ml).  MNC  were depleted of slgE §  and  0 
slgG4 + B cells by panning (10, 15). The percentage of slgE + and  s0- 
slgG4 + B cells was <0.1%.  They were cultured (3  x  10s/0.2 
ml/well) in 96-well U-bottomed microtiter plates (Coster, Cam-  ~ 40- 
bridge, MA) for 14 d with various factors as described in Results.  ~ 30- 
Highly purified B cells were obtained by SRBC rosetting, followed  ~  z0- 
by t-leucine methyl ester incubation as described previously (10,  10- 
15). Purified B cell fractions contained, <1% CD3 + T cells, <1% 
CD14 + monocytes, <1% CD16 + NK cells and >98% CD20 § B  c 
cells. Purified B cells were depleted of slgE § and/or sIgG4  + B cells  s0o- 
by panning. The percentages, respectively, of slgE ~ and slgG4*  ~ 400- 
B cells in the slgE- and slgG4-  B cell fractions were <0.1%. Al- 
ternatively, slgE + and slgG4 + B cells were enriched from tonsils  ~ 300- 
of atopic patients by repeated panning. Purified slgE § and slgG4  §  ~ ~00- 
B cell fractions contained >98% slgE  § B cells and >98% slgG4 §  ,00- 
B cells, respectively (10, 15). In nonatopic donors, slgE + and  0 
slgG4 + B cell fractions could not be obtained because of paucity 
of these cells. They were cultured for 14 d as described in Results.  500- 
Control cultures for the evaluation of preformed Ig were carried  ~ 400d 
out in the presence of cycloheximide  (100/~g/ml). The amount  ~ 3oo- 
of IgE, IgG subclasses, IgM, and IgA subclasses in the superna-  ~ zoo 
tents were determined by ELISA (10, 13). 
In some experiments, MNC (3  x  10s/0.2 ml/well) or B cells  ~00 
(1  x  10s/0.2 ml/well) were cultured with or without factors for  0 
4 d, and concentrations of GH, IGF-I, or Ib4 were measured by 
ELISA or R.IA (16, 17). 
Results 
Preliminary experiments have shown that in MNC, medium 
alone failed to induce IgE (<0.15  ng/ml, n  =  10) or IgG4 
(<0.3 ng/ml, n  --  10) production, whereas GI-I and IGF-I 
at 250 ng/ml induced IgE (4.1  +  2.7 and 5.2  _+  2.4 ng/ml, 
respectively, n  --  10) and IgG4 (33.0  _+  7.4 and 41.7  +_  7.2 
ng/ml, respectively, n --  10) production. To rule out the pos- 
sibility that GH- and IGF-I-induced IgE and IgG4 produc- 
tion may result from the expansion of a small  slgE + and 
slgG4 § B cell population,  MNC were depleted of slgE + 
and slgG4 § B cells, and they were cultured with peptides. 
As shown in Fig.  1, A-H,  GH and IGF-I induced IgE and 
IgG4 production in a dose-dependent fashion, whereas they 
failed to induce IgM, IgG1, IgG2, IgG3, IgA1, and IgA2 
production. In contrast, IGF-II and insulin failed to induce 
IgE (<0.15 ng/ml) or IgG4 (<0.3 ng/ml) or other Ig produc- 
tion (Fig.  1, A-H). 
It has been reported that GH-induced stimulation was medi- 
ated by endogenously produced IGF-I (17, 18), although we 
and others (13, 19, 20) have reported the direct enhancing 
effect of GH. It has also been reported that IL-4 and IL-13 
induced IgE and IgG4 production, and that IFN-ot and IFN-y 
antagonized induction by them (1, 3, 11, 12, 21). Therefore, 
we compared the inducing effects of GH and IGF-I with those 
of IL-4 and IL-13. As shown in Fig. 2, GH-induced IgE and 
IgG4 production was blocked by anti-GH Ab, whereas nei- 
ther anti-IGF-I Ab nor anti-IL-4 Ab nor anti-IL-13 Ab did 
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Figure 1.  Effects  of peptides on Ig production  by MNC from  nonatopic 
donors. MNC were depleted of slgE  + and slgG4  + B cells, and were cul- 
tured (3  x 105/well)  with medium  (O) or increasing concentrations  of 
GH (O), IGF-I (O), IGF-II (A), or insulin (A). After 14 d of culture, 
IgE (A), IgG4 (B), IgM (C), IgG1 (D), IgG2 (E), lgG3 (F), IgA1 (G), 
and IgA2 (/4) production were determined. Values are means _+  1 SD 
of triplicate cultures from two experiments. 
so. Addition of anti-GH receptor Ab also blocked induction, 
whereas anti-IGF-I receptor mAb failed to do so (data not 
shown). Moreover,  neither IFN-ct nor IFN-), antagonized 
the effect of GH (Fig. 2). Conversely, IGF-I-induced IgE and 
IgG4 production was blocked by anti-IGF-I Ab, whereas none 
of the anti-GH Ab, anti-IL-4 Ab, anti-IL-13 Ab, IFN-ol, or 
IFN-qr had any effect. Addition of anti-IGF-I receptor mAb 
also blocked induction whereas anti-GH receptor mAb failed 
to do so (data not shown). In contrast, IL-4- and IL-13-in- 
duced IgE and IgG4 production was blocked by anti-IL-4 
Ab and anti-IL-13 Ab, respectively,  but not by anti-GH or 
anti-IGF-I Ab, and induction was antagonized by IFN-ot and 
IFN-3~ (Fig.  2). 
We also measured GH, IGF-I, and IL-4 concentrations in 
culture supernatants. To do this, MNC were cultured with 
or without GH (250 ng/ml) for measurement of IGF-I or 
IL-4, and, conversely, they were cultured with or without 
IGF-I (250 ng/ml) for measurement of GH or IL-4. On the 
other hand, they were cultured with or without IL-4 (1,000 
U/ml) for measurement of GH or IGF-I. Cultured superna- 
tents did not contain detectable levels of GH (<10 pg/ml), 
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GH and IGF-I on lgE and IgG4 produc- 
tion by MNC from nonatopic donors. 
MNC  from  nonatopic  donors  were 
depleted of slgE + and slgG4 + B cells, 
and were cultured (3  x  1@/well) with 
indicated factors. GH was used at 250 
ng/ml,  IGF-I  at  250  ng/ml,  11..4 at 
1,000 U/ml, IL-13 at 50 ng/ml, and all 
the Abs at 10 #g/ml, IFN-c~ at 1,000 
U/ml and IFN-3' at 1,000 U/ml. After 
14 d of culture,  IgE (A) and IgG4 (B) 
production were determined. Values are 
means  _+  1 SD of triplicate cultures. 
IGF-I  (<30 pg/ml),  or IL-4  (<40 pg/ml),  and addition of 
GH,  IGF-I,  or IL-4  failed  to  induce them. 
We next studied the effects of GH and IGF-I on IgE and 
IgG4 production by purified  B cells with or without anti- 
CD40 mAb (2, 4-6).  As shown in Fig.  3,  slgE-,  slgG4- 
B  cells  failed  to  produce detectable  levels  of IgE or IgG4. 
Neither anti-CD40 mAb nor GH induced them. However, 
GH plus anti-CD40 mAb induced IgE and IgG4 production 
which was blocked by anti-GH  Ab  and anti-GH  receptor 
mAb (data not shown), whereas none of the anti-IGF-I  Ab, 
anti-IGF-I receptor mAb (data not shown), anti-IL-4 Ab, or 
anti-IL-13  Ab did so. Similarly, IGF-I plus anti-CD40 mAb 
induced IgE and IgG4 production,  whereas IGF-I alone failed 
to  do  so.  Induction by  IGF-I  plus  anti-CD40  mAb  was 
specifically blocked by anti-IGF-I  Ab or anti-IGF-I  receptor 
mAb (data not shown), but not by anti-GH Ab,  anti-GH 
receptor mAb (data not shown), anti-IL-4 Ab, or anti-IL-13 
Ab. Moreover, no detectable levels ofGH, IGF-I or IL-4 were 
induced in cultures  of these B cells.  In contrast  to GH and 
IgF-I, neither IGF-II plus anti-CD40 mAb nor insulin plus 
anti-CD40 mAb induced IgE (<0.15 ng/ml) or IgG4 (<0.3 
ng/ml)  production by slgE-,  slgG4-  B cells. 
We then studied  the effects of GH and IGF-I on sponta- 
neous IgE and IgG4 production by atopic patients'  B cells. 
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Figure  3.  Effects of  GH  and 
IGF-I on IgE and IgG4 production 
by B cells from nonatopic  donors. 
B cell from nonatopic donors were 
depleted of slgE  + and slgG4 + cells 
(slgE-, slgG4-  B cells), and they 
were cultured (10S/well) with indi- 
cated factors. Anti-CD40 mAb were 
used  at  0.1  /xg/ml,  GH  at  250 
ng/ml, IGF-I at 250 ng/ml, and all 
the Abs at 10/~g/ml. After 14 d of 
culture,  IgE  (ll)  and  IgG4  (13) 
production were determined. Values 
are  means  +  1  SD  of triplicate 
cultures. 
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atopic patients were separated and cultured with medium or 
factors. As shown in Fig. 4 A, sIgE + B cells spontaneously 
produced IgE, which was not enhanced by GH plus anti- 
CD40 mAb or by IGF-I plus anti-CD40 mAb. (Expts./-3). 
Fig.  4 A  also showed that none of anti-GH or anti-IGF-I 
Ab (Expt. I), or anti-IL-4 or anti-IL-13 Ab (Expt. 2), or IFN-o~ 
or IFN-'y (Expt.  3) affected IgE production by slgE + B ceils. 
In contrast, sIgE- B cells did not produce IgE with medium 
alone.  However,  GH plus anti-CD40 mAb or IGF-I plus 
anti-CD40 mAb induced IgE production by slgE-  B cells, 
which was blocked by anti-GH and anti-IGF-I Ab, respec- 
tivdy (Expt. 1), but not by anti-IL-4 or anti-IL-D Ab (Expt. 2), 
or by IFN-ot or IFN-~'  (Expt.  3). 
Identical results  were observed in  IgG4 production by 
slgG4 + or slgG4-  B cells. As shown in Fig.  4 B, neither 
GH plus anti-CD40 mAb nor IGF-I plus anti-CD40 mAb 
affected IgG4 production by sIgG4 + B cells, whereas they 
induced IgG4 production by sIgG4-  B ceils. Induction by 
GH and IGF-I was specifically blocked by anti-GH Ab and 
anti-IGF-I  Ab,  respectively  (Expt.  I),  whereas it  was  not 
blocked by any of the anti-IL-4 Ab or anti-IL-13  Ab (Expt. 
2),  or by IFN-o~ or IFN-'y (Expt.  3). 
Discussion 
We have demonstrated that GH and IGF-I specifically in- 
duced IgE and IgG4 production by normal donors' MNC 
depleted of slgE + and slgG4 + B cells, whereas  IGF-II and 
insulin failed to do so. The detailed mechanisms of differen- 
tial effects of these peptides are currently under investiga- 
tion. However, this is not surprising. We and others (13, 22, 
23) have reported that GH and IGF-I stimulated plasma cells, 
pre-T cells, and neutrophils, whereas IGF-II or insulin were 
either less stimulatory or without effect. 
It has been reported that GH-induced stimulation was medi- 
ated by IGF-I, although a direct stimulating effect of GH 
was also reported (13, 17-20). Moreover, IL-4 and IL-13 have 
been shown to induce IgE and IgG4 production (1-3,  11, 
12). However, our results indicate that GH effect was specific, 
and was not mediated by IGF-I, IL-4, or IL-13, because GH- 
induced IgE and IgG4 production was blocked by anti-GH 
Ab, but not by anti-IGF-I Ab, anti-IL-4 Ab, or anti-IL-13 
Ab. In addition, whereas IFN-a and IFN-3, inhibited IL-4- 
and IL-13-induced IgE and IgG4 production, they had no 
effect on GH- or IGF-I-induced IgE and IgG4 production. 
Furthermore, no IGF-I or IL-4 was detectable in the culture 
supernatants with GH. Conversely, IGF-I-induced induction 
was  not mediated by GH,  IL-4,  or IL-13,  because  it was 
blocked by anti-IGF-I Ab, but not by anti-GH Ab, anti-IL-4, 
Ab or anti-IL-13  Ab.  Moreover,  no GH or IL-4 was pro- 
duced by IGF-I. 
GH and IGF-I also induced IgE and IgG4 production by 
normal donors' slgE-, slgG4-  B cells in the presence, but 
not absence, of anti-CD40 mAb. Again, this induction was 
specific to each peptide. These results indicate that GH- and 
IGF-I-induced IgE and IgG4 production was due to switching 
but not to expansion of slgE + and slgG + B cells. This was 
directly shown by using slgE +, slgG4 +, slgE-, or slgG4- 
B cells from atopic patients. Whereas GH plus anti-CD40 
mAb or IGF-I plus anti-CD40 mAb induced IgE and IgG4 
production by slgE-  and slgG4- B cells, respectively, they 
Figure  4.  Effects  of  GH  and 
IGF-I on IgE and IgG4 production 
by  slg +  and  slg-  B  cells  from 
atopic patients.  Purified slgE + or 
slgE- (A), and slgG4 + or slgG4- 
(B) B cells from atopic patients were 
cultured (2  x  104/well) with indi- 
cated factors. Anti-CD40 mAb was 
used  at  0.1  /~g/ml,  GH  at  250 
ng/ml, IGF-I at 250 ng/ml, all the 
Abs at 10/~g/ml, IFN-ot at  1,000 
U/ml, and IFN-3, at 1,000 U/ml. 
After 14 d of culture,  IgE (A) and 
IgG4  (/3) production  were  deter- 
mined.  Values are means  _+  1 SD 
of triplicate  cultures. 
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The  in  vivo influence  of GH and  IGF-I remains  to be 
elucidated. However, it has been reported that alveolar mac- 
rophages from patients with lung disease produced IGF-I, 
and that IgE concentrations in bronchoalveolar lavage (BAL) 
fluid was elevated in those patients  (24, 25).  In accordance 
with this, we have found that GH and IGF-I concentrations 
in BAL fluid were elevated in asthmatic patients:  GH and 
IGF-I  concentrations  in  BAL  fluid  in  asthmatic  patients 
(n  =  5) were 45  +  12 and 61  +  10 pg/ml (n  =  5), respec- 
tively, whereas those in normal  donors  (n  =  5) were <10 
and <30 pg/ml, respectively. Moreover, there are cases with 
IgE deficiency and GH deficiency and low serum levels of 
IGF-I (26). 
GH and IGF-I seem to be excellent reagents in the study 
oflgE and IgG4 regulation. We and others (1-3, 5, 21) have 
reported that various factors modulate IL-4-induced IgE and 
IgG4 production. The interaction  of GH and IGF-I with those 
factors is currently  under investigation. 
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